According to this study, over the next five years the Therapeutic Nuclear Medicines market will register a 18.7% CAGR in terms of revenue, the global market size will reach $ 2345.4 million by 2025, from $ 1182.5 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Therapeutic Nuclear Medicines business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Therapeutic Nuclear Medicines market by type, application, key manufacturers and key regions and countries.
This study considers the Therapeutic Nuclear Medicines value and volume generated from the sales of the following segments:
Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Radium-223
Lutetium-177
Iodine-131
Other
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Thyroid
Bone Metastasis
Lymphoma
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Bayer
Progenics Pharmaceuticals
Novartis AG
Dongcheng
Q BioMed
China Isotope & Radiation
Lantheus
Curium Pharmaceuticals
Spectrum Pharmaceuticals
Jubilant DraxImage
International Isotopes
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Therapeutic Nuclear Medicines consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Therapeutic Nuclear Medicines market by identifying its various subsegments.
Focuses on the key global Therapeutic Nuclear Medicines manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Therapeutic Nuclear Medicines with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Therapeutic Nuclear Medicines submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Therapeutic Nuclear Medicines Consumption 2015-2025
2.1.2 Therapeutic Nuclear Medicines Consumption CAGR by Region
2.2 Therapeutic Nuclear Medicines Segment by Type
2.2.1 Radium-223
2.2.2 Lutetium-177
2.2.3 Iodine-131
2.2.4 Other
2.3 Therapeutic Nuclear Medicines Consumption by Type
2.3.1 Global Therapeutic Nuclear Medicines Consumption Market Share by Type (2015-2020)
2.3.2 Global Therapeutic Nuclear Medicines Revenue and Market Share by Type (2015-2020)
2.3.3 Global Therapeutic Nuclear Medicines Sale Price by Type (2015-2020)
2.4 Therapeutic Nuclear Medicines Segment by Application
2.4.1 Thyroid
2.4.2 Bone Metastasis
2.4.3 Lymphoma
2.4.4 Other
2.5 Therapeutic Nuclear Medicines Consumption by Application
2.5.1 Global Therapeutic Nuclear Medicines Consumption Market Share by Type (2015-2020)
2.5.2 Global Therapeutic Nuclear Medicines Value and Market Share by Type (2015-2020)
2.5.3 Global Therapeutic Nuclear Medicines Sale Price by Type (2015-2020)
3 Global Therapeutic Nuclear Medicines by Company
3.1 Global Therapeutic Nuclear Medicines Sales Market Share by Company
3.1.1 Global Therapeutic Nuclear Medicines Sales by Company (2018-2020)
3.1.2 Global Therapeutic Nuclear Medicines Sales Market Share by Company (2018-2020)
3.2 Global Therapeutic Nuclear Medicines Revenue Market Share by Company
3.2.1 Global Therapeutic Nuclear Medicines Revenue by Company (2018-2020)
3.2.2 Global Therapeutic Nuclear Medicines Revenue Market Share by Company (2018-2020)
3.3 Global Therapeutic Nuclear Medicines Sale Price by Company
3.4 Global Therapeutic Nuclear Medicines Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Therapeutic Nuclear Medicines Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Therapeutic Nuclear Medicines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Therapeutic Nuclear Medicines by Regions
4.1 Therapeutic Nuclear Medicines by Regions
4.2 Americas Therapeutic Nuclear Medicines Consumption Growth
4.3 APAC Therapeutic Nuclear Medicines Consumption Growth
4.4 Europe Therapeutic Nuclear Medicines Consumption Growth
4.5 Middle East & Africa Therapeutic Nuclear Medicines Consumption Growth
5 Americas
5.1 Americas Therapeutic Nuclear Medicines Consumption by Countries
5.1.1 Americas Therapeutic Nuclear Medicines Consumption by Countries (2015-2020)
5.1.2 Americas Therapeutic Nuclear Medicines Value by Countries (2015-2020)
5.2 Americas Therapeutic Nuclear Medicines Consumption by Type
5.3 Americas Therapeutic Nuclear Medicines Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Therapeutic Nuclear Medicines Consumption by Regions
6.1.1 APAC Therapeutic Nuclear Medicines Consumption by Regions (2015-2020)
6.1.2 APAC Therapeutic Nuclear Medicines Value by Regions (2015-2020)
6.2 APAC Therapeutic Nuclear Medicines Consumption by Type
6.3 APAC Therapeutic Nuclear Medicines Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe Therapeutic Nuclear Medicines by Countries
7.1.1 Europe Therapeutic Nuclear Medicines Consumption by Countries (2015-2020)
7.1.2 Europe Therapeutic Nuclear Medicines Value by Countries (2015-2020)
7.2 Europe Therapeutic Nuclear Medicines Consumption by Type
7.3 Europe Therapeutic Nuclear Medicines Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Therapeutic Nuclear Medicines by Countries
8.1.1 Middle East & Africa Therapeutic Nuclear Medicines Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Therapeutic Nuclear Medicines Value by Countries (2015-2020)
8.2 Middle East & Africa Therapeutic Nuclear Medicines Consumption by Type
8.3 Middle East & Africa Therapeutic Nuclear Medicines Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Therapeutic Nuclear Medicines Distributors
10.3 Therapeutic Nuclear Medicines Customer
11 Global Therapeutic Nuclear Medicines Market Forecast
11.1 Global Therapeutic Nuclear Medicines Consumption Forecast (2021-2025)
11.2 Global Therapeutic Nuclear Medicines Forecast by Regions
11.2.1 Global Therapeutic Nuclear Medicines Forecast by Regions (2021-2025)
11.2.2 Global Therapeutic Nuclear Medicines Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Therapeutic Nuclear Medicines Forecast by Type
11.8 Global Therapeutic Nuclear Medicines Forecast by Application
12 Key Players Analysis
12.1 Bayer
12.1.1 Company Information
12.1.2 Therapeutic Nuclear Medicines Product Offered
12.1.3 Bayer Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Bayer Latest Developments
12.2 Progenics Pharmaceuticals
12.2.1 Company Information
12.2.2 Therapeutic Nuclear Medicines Product Offered
12.2.3 Progenics Pharmaceuticals Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Progenics Pharmaceuticals Latest Developments
12.3 Novartis AG
12.3.1 Company Information
12.3.2 Therapeutic Nuclear Medicines Product Offered
12.3.3 Novartis AG Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Novartis AG Latest Developments
12.4 Dongcheng
12.4.1 Company Information
12.4.2 Therapeutic Nuclear Medicines Product Offered
12.4.3 Dongcheng Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Dongcheng Latest Developments
12.5 Q BioMed
12.5.1 Company Information
12.5.2 Therapeutic Nuclear Medicines Product Offered
12.5.3 Q BioMed Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Q BioMed Latest Developments
12.6 China Isotope & Radiation
12.6.1 Company Information
12.6.2 Therapeutic Nuclear Medicines Product Offered
12.6.3 China Isotope & Radiation Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 China Isotope & Radiation Latest Developments
12.7 Lantheus
12.7.1 Company Information
12.7.2 Therapeutic Nuclear Medicines Product Offered
12.7.3 Lantheus Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Lantheus Latest Developments
12.8 Curium Pharmaceuticals
12.8.1 Company Information
12.8.2 Therapeutic Nuclear Medicines Product Offered
12.8.3 Curium Pharmaceuticals Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Curium Pharmaceuticals Latest Developments
12.9 Spectrum Pharmaceuticals
12.9.1 Company Information
12.9.2 Therapeutic Nuclear Medicines Product Offered
12.9.3 Spectrum Pharmaceuticals Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Spectrum Pharmaceuticals Latest Developments
12.10 Jubilant DraxImage
12.10.1 Company Information
12.10.2 Therapeutic Nuclear Medicines Product Offered
12.10.3 Jubilant DraxImage Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 Jubilant DraxImage Latest Developments
12.11 International Isotopes
12.11.1 Company Information
12.11.2 Therapeutic Nuclear Medicines Product Offered
12.11.3 International Isotopes Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2018-2020)
12.11.4 Main Business Overview
12.11.5 International Isotopes Latest Developments
13 Research Findings and Conclusion
List of Tables
Table 1. Research Methodology
Table 2. Data Source
Table 3. Therapeutic Nuclear Medicines Consumption CAGR by Region 2015-2025 ($ Millions)
Table 4. Major